A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Inclusion Criteria:

• 50 to 80 years of age

• Diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD according to National Institute of Aging-Alzheimer's Association (NIA-AA)

• A global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and CDR-Memory Box (CDRMB) score ≥0.5 at Screening and Baseline

• Score of ≤85 for the delayed recall domain of the Repeatable Battery for theAssessment of Neuropsychological Status (RBANS) at Screening

• Mini-Mental State Examination (MMSE) score ≥20 at Screening

• Participant has an identified informant that has and will maintain sufficientcontact (minimum of 5 hours per week) with the participant to be able to provideaccurate information on the participant's cognitive, functional, and emotionalstates and of the participant's personal care

• At least 6 years of formal education after the age of 5 or work experience toexclude mental deficits other than prodromal or mild AD dementia

• Evidence of cerebral Aβ accumulation by either positive amyloid assessment by eitherpositron emission tomography (PET) scan or cerebrospinal fluid pTau181/Aβ1-42 ratioassessment

Exclusion Criteria:

• Any evidence of a condition that may affect cognition other than AD

• Contraindications to PET imaging

• Inability to tolerate or contraindication to magnetic resonance imaging

• Any serious medical condition or abnormality that in the opinion of the investigatorwould preclude safe participation in and completion of the study or interfere withstudy assessments and/or study interpretation

• Alcohol or drug abuse within 2 years of screening

• Use of any experimental therapy within the past 6 months (or 5 half lives) prior toscreening

• Previous treatment with medication intended to treat a neurodegenerative disorder (other than AD) within 1 year of screening

• Chronic daily treatment with atypical antipsychotics, opiates or opioids,benzodiazepines, barbiturates, hypnotics, or any medication with clinicallysignificant centrally acting antihistamine or anticholinergic activitiy

• Received treatment with monoclonal antibodies (mAbs), cytokines, immunoglobulins, orother blood products within 3 months or 5 half-lives (whichever is longer) prior tofirst dosing